Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Heron Therapeutics, Inc.

NASDAQ: HRTX · Life Sciences · 4 alerts · CIK 818033

Share price
$0.2843Close, Nov 16
Market cap
$54.1M
Shares outstanding
190.27MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Heron Therapeutics, Inc. filings on SEC EDGAR ↗

8:51 AM ET 10-Q
Financial Results

Heron Therapeutics Q3 2026 Results: Net Loss of $5.01M, Loss Narrows

Heron Therapeutics filed its 10-Q for the period ended September 30, 2026, reporting 190,273,587 shares of common stock outstanding. The filing highlights a pending Asset Sale to CorMedix and notes significant risks regarding the company's ability to continue as a going concern without additional funding.

Key figure
Net loss $5.01M
8:15 AM ET 8-K
Financial Results

Heron Therapeutics Financial Results

Heron Therapeutics reported Q3 2026 net revenue of $35.3 million, a 7.8% decrease year-over-year, driven by a decline in its Oncology franchise despite growth in Acute Care products ZYNRELEF and APONVIE. The company also announced a definitive agreement to sell substantially all of its assets to CorMedix Therapeutics, subject to stockholder approval. Heron ended the quarter with $23.4 million in cash and cash equivalents and did not provide forward financial guidance.

Counterparty
CorMedix Therapeutics
7:41 AM ET 8-K
Divestiture

Heron Therapeutics Divestiture to CorMedix Inc. for $145M

Heron Therapeutics has entered into a definitive agreement to sell substantially all of its assets to CorMedix Inc. for $145 million in cash and 14,583,333 shares of CorMedix common stock. The deal includes Heron's commercial portfolio (ZYNRELEF, APONVIE, CINVANTI, and SUSTOL) and provides for up to $55 million in potential earn-out payments plus royalties. Heron will remain a standalone public company, using the proceeds to repay its existing debt and evaluate new strategic investments.

Value
$145M
Counterparty
CorMedix Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.